Skip to content
ContentLora

    Tip: press / anywhere to search.

    technology

    Cell-free protein synthesis

    Also known as TXTL, cell-free expression, in vitro transcription-translation

    Cell-free protein synthesis runs transcription and translation outside a living cell, using extracts that let researchers test genetic circuits and make proteins without growing anything.[1] Reported yields reach about 4 milligrams per millilitre in batch reactions, and in August 2026 ARPA-H awarded up to $26 million to DNA Script and GE HealthCare for cell-free DNA bioproduction.[2][3]

    Editor reviewedUpdated Synthetic biologyLife sciencesScience
    Key facts

    What it is

    A cell-free system takes the transcription and translation machinery out of cells and runs it in a tube. The resulting reaction expresses DNA added by the user, which makes it a testbed for genetic regulatory elements and circuits as well as a route to protein product without cultivating an organism.[1] The best-documented family is TXTL, built from Escherichia coli extract.[2]

    Performance

    The all-E. coli TXTL toolbox 3.0 reported protein synthesis of 4 milligrams per millilitre in batch reactions and more than 8 milligrams per millilitre inside synthetic cell compartments such as liposomes.[2] It also assembled bacteriophage T7, a 40-kilobase genome, at 10^13 plaque-forming units per millilitre, which demonstrates that cell-free reactions can execute large multi-gene programmes rather than single proteins.[4]

    Why designers use it

    Three properties drive adoption. There is no growth phase, so results come in hours. The reaction is open, so components and concentrations can be set directly rather than inferred from host physiology. And nothing replicates, which simplifies containment compared with engineered live cultures.[1]

    That makes cell-free the natural first stop for genetic circuit work, where the practical problem is sampling a large design space fast.[5][1] It is also used alongside minimal cell research, where over 90 research groups have worked on stripped-down hosts and their components.[6]

    Towards distributed manufacturing

    Cell-free reactions can in principle be started where the product is needed, which is why the approach attracts public money for on-demand biologics. In August 2026 DNA Script said it and GE HealthCare had been awarded up to $26 million by ARPA-H to advance cell-free DNA bioproduction, with the stated aim of faster, distributed DNA manufacturing for next-generation therapies.[3]

    How it is used in practice

    Three patterns recur. The first is screening: because reactions can be set up in parallel, cell-free extracts are used to test regulatory elements before anything is cloned into a host, complementing the very large in-cell design libraries reported in January 2026.[1][7] The second is assembling biological objects that are awkward to grow, as with the T7 phage synthesis above.[4] The third is production where the point of use matters more than unit cost, which is the thesis behind the August 2026 ARPA-H award for distributed DNA manufacturing.[3]

    Input DNA matters here too: on-site enzymatic synthesis can produce template oligonucleotides in hours, shortening the loop from design to expressed protein.[8]

    Limits

    Cell-free is not a general substitute for fermentation. Yields per litre remain far below what engineered organisms achieve in a tank, which is why food and commodity proteins are made by precision fermentation in fungal hosts rather than in vitro.[2][9] Extract supply, reagent cost and the absence of a self-renewing catalyst all scale against it. The technology’s advantage is speed, siting and control, not unit cost at volume.[1][10]

    Questions readers ask

    What is cell-free protein synthesis?

    Expressing genes in a reaction mixture rather than in living cells, using extracted machinery; it is used to test regulatory elements and circuits, make biologics and build synthetic cells.[1]

    How much protein can a cell-free reaction make?

    The all-E. coli TXTL toolbox 3.0 reported 4 milligrams per millilitre in batch reactions and more than 8 milligrams per millilitre in synthetic cell compartments.[2]

    Can cell-free systems build something as complex as a virus particle?

    Yes. The same platform assembled bacteriophage T7, whose genome is about 40 kilobases, at 10 to the 13th plaque-forming units per millilitre.[4]

    Why is it useful for circuit design?

    Because a tube has no growth phase, regulatory elements and circuits can be tested quickly and without a living host.[1]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      Cell-free transcription-translation (TXTL) systems express genes in a tube using extracted cellular machinery, and are used to test genetic regulatory elements and circuits without living cells. confirmedas of 2021-08-04

    2. [2]

      The all-E. coli TXTL toolbox 3.0 reported protein synthesis of 4 milligrams per millilitre in batch reactions and more than 8 milligrams per millilitre inside synthetic cell compartments. confirmedas of 2021-08-04

    3. [3]

      On 4 August 2026 DNA Script said it and GE HealthCare had been awarded up to $26 million by ARPA-H to advance cell-free DNA bioproduction under the FLASH programme. confirmedas of 2026-08-04

    4. [4]

      The same cell-free platform assembled the bacteriophage T7, whose genome is about 40 kilobases, at 10^13 plaque-forming units per millilitre. confirmedas of 2021-08-04

    5. [5]

      The lead author of the CLASSIC study described finding a working genetic circuit design in the available design space as "like looking for a needle in a haystack". confirmedas of 2026-01-14

    6. [6]

      More than 90 research groups have used or studied the JCVI minimal cell and related strains since the 2016 publication. confirmedas of 2025-06-02

    7. [7]

      On 14 January 2026 a Rice University-led team reported CLASSIC in Nature, a method that combines long-read and short-read sequencing to measure hundreds of thousands to millions of genetic circuit designs in one experiment. confirmedas of 2026-01-14

    8. [8]

      DNA Script's SYNTAX system is a benchtop enzymatic DNA printer that produces custom oligonucleotides on site in hours rather than days. reportedas of 2026-10-10

    9. [9]

      Onego Bio's Bioalbumen is ovalbumin with the same amino acid sequence as chicken egg white protein, made by precision fermentation in the filamentous fungus Trichoderma reesei. confirmedas of 2025-09-24

    10. [10]

      The United States is reported to be severely short of pilot- and demonstration-scale equipment for precision fermentation, which is the stated reason for federal investment in bioindustrial pilot plants. reportedas of 2026-05-11

    Revision history (2)
    1. Page created.
    2. Refresh: re-sourced the TXTL toolbox 3.0 yield and bacteriophage figures to the open-access full text via Europe PMC, with verbatim abstract wording.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Cell-free protein synthesis." ContentLora, updated Oct 10, 2026. https://contentlora.com/wiki/cell-free-protein-synthesis

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    Connections
    JCVI minimal cell Prototyping platform forEnzymatic DNA synth… Input supplied byPrecision fermentat… Alternative to
    ☰ Contents